BioNTech SE American Depositary Share BNTX

BioNTech SE es una empresa de biotecnología con sede en Alemania en etapa clínica. La empresa se enfoca en inmunoterapias específicas para pacientes para el tratamiento del cáncer y otras enfermedades graves. Desarrolla una amplia cartera de productos utilizando diferentes enfoques científicos y plataformas tecnológicas, incluidos candidatos a productos basados en ARNm individualizados, células T con receptor de antígeno quimérico, inmunomoduladores de punto de control, anticuerpos contra el cáncer dirigidos y moléculas pequeñas. Además, la empresa ofrece productos de diagnóstico y servicios de descubrimiento de medicamentos para otras áreas terapéuticas, incluidas enfermedades infecciosas, alergias y trastornos autoinmunes.

• Zacks Investment Research 30 sept

  Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

  Both Moderna and BioNTech are transitioning beyond COVID-19 vaccines into oncology and other therapeutic areas. Moderna has already commercialized RSV and flu vaccines with positive intismeran cancer therapy results, while BioNTech relies more heavily on Comirnaty and has a broader but less advanced oncology pipeline. Moderna is rated as the better investment choice despite trading at a premium valuation, given its further-along transition away from COVID-19 dependency.

  

• GlobeNewswire Inc. 30 sept

  Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

  The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

  

• The Motley Fool 8 sept

  Why Pfizer Stock Was so Healthy in August

  Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

  

• The Motley Fool 3 sept

  BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

  BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

  

• GlobeNewswire Inc. 3 sept

  Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

  DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.